Vaccinex Inc.

0.60
-0.16 (-21.05%)
At close: Apr 03, 2025, 12:23 PM

Company Description

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs.

The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders.

Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma.

The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders.

Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.

Vaccinex Inc.
Vaccinex Inc. logo
Country United States
IPO Date Aug 9, 2018
Industry Biotechnology
Sector Healthcare
Employees 37
CEO Dr. Maurice Zauderer Ph.D.

Contact Details

Address:
1895 Mount Hope Avenue
Rochester, New York
United States
Website https://www.vaccinex.com

Stock Details

Ticker Symbol VCNX
Exchange OTC
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001205922
CUSIP Number 918640103
ISIN Number US9186403013
Employer ID 16-1603202
SIC Code 2834

Key Executives

Name Position
Dr. Maurice Zauderer Ph.D. Co-Founder, Chief Executive Officer, President & Director
Dr. Elizabeth E. Evans Ph.D. Chief Operating Officer and Senior Vice President of Discovery & Translational Medicine
Jill Sanchez CPA Chief Financial Officer
Dr. Ernest S. Smith Ph.D. Senior Vice President of Research & Chief Scientific Officer
Dr. John E. Leonard Ph.D. Senior Vice President of Development

Latest SEC Filings

Date Type Title
Apr 01, 2025 NT 10-K Filing
Mar 27, 2025 15-12G Filing
Mar 25, 2025 POS AM Filing
Mar 25, 2025 POS AM Filing
Mar 25, 2025 POS AM Filing
Mar 25, 2025 POS AM Filing
Mar 25, 2025 POS AM Filing
Mar 25, 2025 POS AM Filing
Mar 25, 2025 POS AM Filing
Mar 25, 2025 POS AM Filing